1. Home
  2. SRPT
  3. SRPT News

Latest Sarepta Therapeutics Inc. (DE) (SRPT) News on May 10, 2025

Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?
SRPT

Insider Monkey

15 hours ago

Is Sarepta Therapeutics, Inc. (SRPT) The Best Stock That Will Bounce Back?

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference
SRPT

Business Wire

a day ago

Sarepta Therapeutics to Present at the BofA Securities Health Care Conference

Sarepta price target lowered to $125 from $183 at Needham
SRPT

TipRanks

2 days ago

Sarepta price target lowered to $125 from $183 at Needham

SRPT

MT Newswires

2 days ago

UBS Cuts Price Target on Sarepta Therapeutics to $85 From $188, Keeps Buy Rating

Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags
SRPT

Simply Wall St.

2 days ago

Sarepta Therapeutics First Quarter 2025 Earnings: Revenues Beat Expectations, EPS Lags

Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday
SRPT

Insider Monkey

2 days ago

Why Sarepta Therapeutics, Inc. (SRPT) Nosedived on Wednesday

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks
SRPT

StockStory

2 days ago

Q1 Earnings Recap: AbbVie (NYSE:ABBV) Tops Therapeutics Stocks

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)
SRPT

StockStory

2 days ago

Therapeutics Stocks Q1 Results: Benchmarking Sarepta Therapeutics (NASDAQ:SRPT)

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low
SRPT

Investor's Business Daily

2 days ago

The 'Double Whammy' That Sent Sarepta Stock To An Eight-Year Low

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why
SRPT

StockStory

2 days ago

Sarepta Therapeutics (SRPT) Stock Trades Down, Here Is Why

Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire.
SRPT

Barrons.com

2 days ago

Sarepta Therapeutics Stock Plunges on Guidance Cut. Its ‘Moneymaker’ Is Under Fire.

SRPT

Thomson Reuters StreetEvents

3 days ago

Q1 2025 Sarepta Therapeutics Inc Earnings Call

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut
SRPT

Zacks

3 days ago

SRPT Q1 Earnings Miss, Sales Beat, Stock Slides 21% on '25 View Cut

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales
SRPT

Pharmaceutical Technology

3 days ago

Sarepta shares fall amid FDA’s CBER appointment and weak Elevidys sales

Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...
SRPT

GuruFocus.com

3 days ago

Sarepta Therapeutics Inc (SRPT) Q1 2025 Earnings Call Highlights: Robust Revenue Growth Amidst ...

Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics
SRPT

Zacks

3 days ago

Compared to Estimates, Sarepta Therapeutics (SRPT) Q1 Earnings: A Look at Key Metrics

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%
SRPT

StockStory

3 days ago

Sarepta Therapeutics (NASDAQ:SRPT) Surprises With Q1 Sales But Stock Drops 22.8%

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates
SRPT

Zacks

3 days ago

Sarepta Therapeutics (SRPT) Reports Q1 Loss, Tops Revenue Estimates

SRPT

MT Newswires

3 days ago

Sarepta Therapeutics Swings to Non-GAAP Q1 Loss; Shares Tumble After Hours

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow
SRPT

StockStory

5 days ago

Earnings To Watch: Sarepta Therapeutics (SRPT) Reports Q1 Results Tomorrow

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks
SRPT

TipRanks

6 days ago

Oppenheimer Predicts Up to ~840% Surge for These 2 ‘Strong Buy’ Stocks

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution
SRPT

StockStory

9 days ago

1 of Wall Street’s Favorite Stock on Our Buy List and 2 to Approach with Caution

Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
SRPT

Zacks

10 days ago

Geron (GERN) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now
SRPT

Insider Monkey

10 days ago

Why Sarepta Therapeutics, Inc. (SRPT) is Among the Best Oversold NASDAQ Stocks to Buy Right Now

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth
SRPT

Zacks

11 days ago

Sarepta Therapeutics (SRPT) Reports Next Week: Wall Street Expects Earnings Growth

Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential
SRPT

Insider Monkey

16 days ago

Sarepta Therapeutics (SRPT): Among Billionaire George Soros’ Small-Cap Stocks with Huge Upside Potential

SRPT

Argus Research

17 days ago

SRPT: Raising target price to $47.00

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results
SRPT

Business Wire

18 days ago

Sarepta Therapeutics to Announce First Quarter 2025 Financial Results

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts?
SRPT

Insider Monkey

18 days ago

Is Sarepta Therapeutics, Inc. (SRPT) the Most Promising Long-Term Stock According to Analysts?

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost
SRPT

Investor's Business Daily

18 days ago

Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost

Exploring 3 High Growth Tech Stocks In The US Market
SRPT

Simply Wall St.

21 days ago

Exploring 3 High Growth Tech Stocks In The US Market

SRPT

MT Newswires

23 days ago

BofA Adjusts Price Target on Sarepta Therapeutics to $157 From $179, Keeps Buy Rating

Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week
SRPT

Simply Wall St.

23 days ago

Sarepta Therapeutics (NASDAQ:SRPT investor one-year losses grow to 54% as the stock sheds US$166m this past week

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies
SRPT

Zacks

24 days ago

SRPT Provides Pipeline Updates on Rare Muscular Disorder Therapies

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks
SRPT

StockStory

24 days ago

Unpacking Q4 Earnings: AbbVie (NYSE:ABBV) In The Context Of Other Therapeutics Stocks

SRPT

Argus Research

24 days ago

SRPT: Raising target price to $44.00

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs
SRPT

Business Wire

25 days ago

Sarepta Therapeutics Announces Pipeline Progress for Multiple Limb-Girdle Muscular Dystrophy Programs

SRPT

MT Newswires

a month ago

Wells Fargo Initiates Sarepta Therapeutics at Overweight With $115 Price Target

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb
SRPT

Zacks

a month ago

The Zacks Analyst Blog Highlights Pacira Biosciences, Edgewise, Sarepta Therapeutics, Amgen and Bristol Myers Squibb

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More
SRPT

Zacks

a month ago

Biotech Stock Roundup: PCRX Up on Patent News, EWTX Down on Study Data & More

SRPT

Argus Research

a month ago

SRPT: Lowering target price to $39.00

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead
SRPT

StockStory

a month ago

3 Reasons to Avoid SRPT and 1 Stock to Buy Instead

SRPT

MT Newswires

a month ago

Oppenheimer Adjusts Price Target on Sarepta Therapeutics to $184 From $215, Keeps Outperform Rating

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street
SRPT

Motley Fool

a month ago

4 Beaten-Down Stocks That Could Skyrocket by 50% to 543%, According to Wall Street

Sarepta and Roche aim to resume paused Elevidys trials following patient death
SRPT

Clinical Trials Arena

a month ago

Sarepta and Roche aim to resume paused Elevidys trials following patient death

Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death
SRPT

Investopedia

a month ago

Sarepta Therapeutics Stock Falls as Some Trials Halted After Patient Death

SRPT

MT Newswires

a month ago

Sarepta Says EU Regulators Temporarily Halt Enrollment, Dosing in Elevidys Trials

Sarepta price target lowered to $183 from $202 at Needham
SRPT

TipRanks

a month ago

Sarepta price target lowered to $183 from $202 at Needham

Sarepta Therapeutics Provides Update on ELEVIDYS
SRPT

Business Wire

a month ago

Sarepta Therapeutics Provides Update on ELEVIDYS

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy
SRPT

Zacks

a month ago

SRPT Stock Down After EMA Places Clinical Hold on DMD Gene Therapy

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy
SRPT

Investor's Business Daily

a month ago

Sarepta Dives On 'Another Unfortunate Development' For Its Gene Therapy

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death
SRPT

Benzinga

a month ago

Sarepta/Roche Suspend Elevidys Gene Therapy Trials In Europe After Patient Death

SRPT

MT Newswires

a month ago

Sarepta Shares Fall After EMA Reportedly Places Hold on Elevidys Trial Enrollment for Duchenne Muscular Dystrophy

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death
SRPT

Investor's Business Daily

a month ago

Sarepta Plunges After EMA Puts Gene Therapy Studies On Hold Following Teen's Death

SRPT

MT Newswires

a month ago

Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $70 From $99, Maintains Hold Rating

Roche halts testing of Sarepta Duchenne gene therapy in Europe
SRPT

BioPharma Dive

a month ago

Roche halts testing of Sarepta Duchenne gene therapy in Europe

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks
SRPT

StockStory

a month ago

Q4 Earnings Outperformers: Amgen (NASDAQ:AMGN) And The Rest Of The Therapeutics Stocks

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Shares Rise After HC Wainwright Upgrade

SRPT

MT Newswires

a month ago

HC Wainwright Upgrades Sarepta Therapeutics to Neutral From Sell, Price Target is $75

SRPT

Argus Research

a month ago

SRPT: Lowering target price to $50.00

Sarepta price target lowered to $179 from $210 at BofA
SRPT

TipRanks

a month ago

Sarepta price target lowered to $179 from $210 at BofA

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz
SRPT

TipRanks

a month ago

Rocket acquires Mr. Cooper, Musk’s xAI acquires X: Morning Buzz

Biotech stocks slide as Marks resignation seen being negative for sector
SRPT

TipRanks

a month ago

Biotech stocks slide as Marks resignation seen being negative for sector

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SRPT

Business Wire

a month ago

Sarepta Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'
SRPT

Investor's Business Daily

a month ago

Biotechs Hammered After FDA Official Resigns, Citing RFK Jr.'s 'Misinformation And Lies'

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving
SRPT

StockStory

a month ago

Why Sarepta Therapeutics (SRPT) Stock Is Nosediving

SRPT

MT Newswires

a month ago

Sarepta Therapeutics Faces Uncertainty Amid FDA Changes, Patient Death, RBC Says

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street
SRPT

The Wall Street Journal

a month ago

Biotech Investors Rush for the Exits After FDA Official Resigns: Heard on the Street

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns
SRPT

Investor's Business Daily

a month ago

Moderna, Vaxcyte, Novavax Hammered After Key FDA Official Peter Marks Resigns

Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out
SRPT

The Wall Street Journal

a month ago

Moderna, Novavax Stocks Fall After Top FDA Vaccine Official Forced Out

SRPT

MT Newswires

a month ago

RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Adjusts PT to $87 From $161

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?
SRPT

Insider Monkey

a month ago

Is Sarepta Therapeutics (SRPT) the Best Mid Cap Biotech Stock to Buy?

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?
SRPT

Zacks

a month ago

Sarepta Therapeutics (SRPT) Down 30.3% Since Last Earnings Report: Can It Rebound?

SRPT

Argus Research

a month ago

SRPT: What does Argus have to say about SRPT?

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion
SRPT

Zacks

2 months ago

How to Play SRPT Stock After Patient Death Post DMD Therapy Infusion

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks
SRPT

StockStory

2 months ago

Q4 Rundown: Moderna (NASDAQ:MRNA) Vs Other Therapeutics Stocks

Is This Stock a Buy After a Massive 20% Drop in 1 Day?
SRPT

Motley Fool

2 months ago

Is This Stock a Buy After a Massive 20% Drop in 1 Day?

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)
SRPT

StockStory

2 months ago

Q4 Earnings Review: Therapeutics Stocks Led by BioMarin Pharmaceutical (NASDAQ:BMRN)

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics
SRPT

Zacks

2 months ago

The Zacks Analyst Blog Highlights Sarepta Therapeutics, Incyte, Gilead Sciences and VTv Therapeutics

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More
SRPT

Zacks

2 months ago

Biotech Stock Roundup: Patient Death Hits SRPT, INCY Study Data & More

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?
SRPT

Zacks

2 months ago

Strength Seen in Sarepta Therapeutics (SRPT): Can Its 8.7% Jump Turn into More Strength?

Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?
SRPT

Insider Monkey

2 months ago

Why Sarepta Therapeutics Inc. (SRPT) Went Up On Wednesday?

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion
SRPT

Zacks

2 months ago

SRPT Nosedives 27% on Patient Death Following DMD Therapy Infusion

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?
SRPT

Insider Monkey

2 months ago

Why Sarepta Therapeutics Inc. (SRPT) Crashed On Tuesday?

Company News for Mar 19, 2025
SRPT

Zacks

2 months ago

Company News for Mar 19, 2025

Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.
SRPT

Investor's Business Daily

2 months ago

Sarepta's 27% Sell-Off Is 'Overblown,' 'Overdone' And 'Overly Bearish.' Here's Why It Happened.

SRPT

MT Newswires

2 months ago

Sector Update: Health Care

SRPT

MT Newswires

2 months ago

Sarepta Therapeutics Says Patient Dies After Elevidys Gene Therapy for Duchenne Muscular Dystrophy; Shares Fall

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges
SRPT

Benzinga

2 months ago

Sarepta Therapeutics Reports Patient Death Post Elevidys Gene Therapy Treatment, Stock Plunges

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies
SRPT

Investor's Business Daily

2 months ago

Sarepta Therapeutics Plummets 23% After Gene Therapy Recipient Dies

Exploring 3 High Growth Tech Stocks In The US Market
SRPT

Simply Wall St.

2 months ago

Exploring 3 High Growth Tech Stocks In The US Market

Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position
SRPT

Simply Wall St.

2 months ago

Statutory Earnings May Not Be The Best Way To Understand Sarepta Therapeutics' (NASDAQ:SRPT) True Position

SRPT

Argus Research

2 months ago

SRPT: Lowering target price to $82.00

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4
SRPT

StockStory

2 months ago

Spotting Winners: Sarepta Therapeutics (NASDAQ:SRPT) And Therapeutics Stocks In Q4

Sarepta price target lowered to $210 from $217 at BofA
SRPT

TipRanks

2 months ago

Sarepta price target lowered to $210 from $217 at BofA

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program
SRPT

Business Wire

2 months ago

Sarepta Therapeutics Announces Call for Applications for the 8th Annual Route 79, The Duchenne Scholarship Program

Sarepta Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
SRPT

Simply Wall St.

2 months ago

Sarepta Therapeutics Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags

SRPT

Thomson Reuters StreetEvents

2 months ago

Q4 2024 Sarepta Therapeutics Inc Earnings Call

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales
SRPT

Zacks

2 months ago

Sarepta Q4 Earnings Lag Estimates, Revenues Gain on Gene Therapy Sales

SRPT

MT Newswires

2 months ago

Deutsche Bank Adjusts Sarepta Therapeutics Price Target to $124 From $136, Maintains Hold Rating

Share on Social Networks: